Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost…
Central Nervous System
-
-
Novartis returns to alpha-synuclein with $2.2bn Arrowhead deal
Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to…
-
Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval
The US Food and Drug Administration (FDA) has approved a once-weekly autoinjector version of Eisai’s Alzheimer’s drug Leqembi (lecanemab), as…
-
Amylyx culls rare neurological disorder programme after trial failure
Amylyx Pharmaceuticals has discontinued a clinical programme evaluating a neuronal cell death inhibitor as a result of disappointing data when tested…
-
Apertura signs multiple licensing agreements for TfR1 CapX tech
Apertura Gene Therapy has entered several licensing agreements to advance central nervous system (CNS) treatments using its transferrin receptor 1…
-
Japan MHLW approves Biostar’s angel stem cell therapy for autism
Biostar Stem Cell Technology Research Institute has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its…
-
Teva’s Ajovy becomes first migraine prevention drug approved for children
The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents,…
-
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supernus and Sage entered a definitive…
-
MetrioPharm gains orphan drug status from EMA for MP1032
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular…
-
Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery…
